Cucurbitacins: Potential candidates targeting mitogen-activated protein kinase pathway for treatment of melanoma

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 29, Issue 2, 2014, Pages 162-167

  Ahmed, Mahmoud S ^a   Halaweish, Fathi T ^a  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Cucurbitaceae; MEK; Mutant B RAF; Triterpenoids

Indexed keywords

23 ENOL CUCURBITACIN E; 24 ENOL CUCURBITACIN E; CUCURBITACIN; CUCURBITACIN A; CUCURBITACIN B; CUCURBITACIN C; CUCURBITACIN D; CUCURBITACIN D GLUCOSIDE; CUCURBITACIN E; CUCURBITACIN E GLUCOSIDE; CUCURBITACIN F; CUCURBITACIN J; CUCURBITACIN K; CUCURBITACIN L; CUCURBITACIN Q; CUCURBITACIN R; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ELISA KIT; ENZYME PHOSPHORYLATION; IC 50; MELANOMA; MELANOMA CELL; MOLECULAR DOCKING; PHARMACOPHORE; PRIORITY JOURNAL; VIRTUAL REALITY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CUCURBITACINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84883069606     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2012.762646     Document Type: Article

References (34)

1. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012;75:311-35.
2. Spits-Tanin T, Grossman S, Dovrat S, et al. Growth inhibitory activity of cucurbitacin glucosides isolated from Citrillus colocynthis on human breast cancer cells. Biochem Pharmacol 2007;73:56-67.
3. Lavie D, Glotter E. The cucurbitacins, a group of tetracyclic triterpenes. In: Herz W, Grisebach H, Kirby GW, eds. Progress in the chemistry of organic natural products. New York: Springer-Verlag; 1971:307-62.
4. Miro M. Cucurbitacins and their pharmacological effects. Phytother Res 1995;9:159-68.
5. Chen JC, Chiu MH, Nie RL, et al. Cucurbitacins and cucurbitane glucosides. Structure and biological activities. Nat Prod Rep 2005;22:386-99.
6. Huang Y, de Bruyne T, Apers S, et al. Complement-inhibiting cucurbitacin glycosides from Picriea fel-terrae. J Nat Prod 1998;61:757-61.
7. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006;20:2149-82.
8. Petermann KB, Rozenberg GI, Zedek D, et al. CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 2007;12:3922-7.
9. Sun J, Blaskovich MA, Jove R, et al. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent anti tumor activity. Oncogene 2005;24:3236-45.
10. Bernard SA, Olayinka OA. Search for a novel antioxidant, antiinflammatory/ analgesic or anti-proliferative drug: cucurbitacins hold the ace. J Med Plants Res 2010;4:2821-6.
11. Bartallis J, Halaweish FT. In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines. Bioorg Med Chem 2011;19:2757-66.
12. Oh H, Mun Y-J, Im S-J, et al. Cucurbitacins from Trichosanthes kirilowii as the inhibitory components on tyrosinase activity and melanin synthesis of B16/F10 melanoma cells. Planta Med 2002;68:832-3.
13. Chan KT, Li K, Liu SL, et al. Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. Cancer Lett 2010;289:46-52.
14. Blaskovich MA, Sun J, Cantor A, et al. Discover of JIS-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003;63:1270-9.
15. Fujita M, Zhu X, Sasaki K, et al. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol 2008;180:2089-98.
16. Sun J, Blaskovich MA, Jove R, et al. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 2005;24:3236-45.
17. Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Annu Rev Biochem 1998;67:227-64.
18. Horvath CM, Darnell JE. The state of the STATs: recent developments in the study of signal transduction to the nucleus. Curr Opin Cell Biol 1997;9:233-9.
19. Ihle JN, Kerr IM. JAKs and STATs in signaling by the cytokine receptor super family. Trends Genet 1995;11:69-74.
20. Schindler C, Darnell Jr, JE. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 1995;64:621-51.
21. Niu G, Heller R, Catlett-Falcone R, et al. Gene therapy with dominant-negative STAT3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999;59:5059-63.
22. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-15.
23. Fecher LA, Cummings SD, Keefe MJ, Alani RM. Toward a molecular classification of melanoma. J Clin Oncol 2007;25:1606-20.
24. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
25. Pollock PM, Meltzer PS. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2002;2:5-7.
26. Thompson N, Lyons J. Recent progress in targeting the Raf/MEK/ ERK pathway in cancer drug discovery. Curr Opin Pharmacol 2005;5:350-6.
27. Ciuffreda L, Bufalo DD, Desideri M, et al. Growth-inhibitory and antiangiogenic the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia 2009;8:720-31.
28. Wang JY, Wilcoxen KM, Nomoto K, Wu S. Recent advances of MEK inhibitors and their clinical progress. Curr Top Med Chem 2007;7:1364-78.
29. Noble MEM, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004;303:1800-5.
30. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
31. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26.
32. Garcia-Echeverria C. Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways. Purinergic Signal 2009;5:117-25.
33. Pollack MS, Heagney SD, Livingston PO, Fogh J. HLA-A,B,C and DR alloantigen expression on forty-six cultured human tumor cell lines. J Natl Cancer Inst 1981;66:1003-12.
34. Iverson C, Larson G, Lai C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res 2009;17:6829-47.